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Background: The use of highly active antiretroviral therapy (HAART) results in multiple side
effects that may jeopardize the life of the patient being treated with antiretroviral drugs. In
resource-poor settings it is difficult to definitively diagnose lactic acidosis by laboratory mea-
surement of lactate. Point-of-care (POC) devices are helpful in the measurement of lactate levels
and have been validated in the intensive care unit setting, but not in a busy outpatient clinic. The
objective of this study was to assess the sensitivity and specificity of the Accutrend1 lactate
meter in the diagnosis of hyperlactatemia/lactic acidosis in patients on nucleoside reverse
transcriptase inhibitor (NRTI)-containing regimens (stavudine).
Design and methods: This was a cross-sectional study of 120 patients on HAART (lamivudine,
stavudine, efavirenz, or nevirapine) with symptoms of/or recovering from hyperlactatemia/
lactic acidosis. Simultaneous testing of the same blood sample was undertaken on the Accu-
trend1 handheld lactate analyzer and a reference instrument (Beckman CX7 Synchron1
machine). A venous lactate level <2.2 mmol/l was considered as normal.
Results: Themean lactate value obtained from the Accutrend1meter was 2.89 mmol/l and from
the reference instrument was 2.78 mmol/l. The standard deviation for Accutrend1 meter was
1.14 mmol/l vs.1.42 mmol/l for the Beckman instrument. The sensitivity obtained for the
Accutrend1 meter was 95.9% (95% CI 87.7—98.9%) and the specificity 63.8% (95% CI 48.5—
76.9%). The positive predictive value was 80.5% (95% CI 70.3—87.9%) and the negative predictive
value was 90.9% (95% CI 74.5—97.6%).
Conclusions: The Accutrend1 lactate meter is an appropriate device for screening patients on
HAART with symptoms of hyperlactatemia/lactic acidosis. The use of this device decreases* Corresponding author. Greys Hospital, Townbush Road, Pietermaritzburg 3201, South Africa.
E-mail address: halimadawood@gmail.com (H. Dawood).
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analytic and intervention time, preventing further morbidity and mortality in patients on an NRTI
(stavudine)-based regimen.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Highly active antiretroviral therapy (HAART) is an important
step in the fight against HIV/AIDS worldwide. However, the
use of HAART has resulted in multiple adverse events that
complicate and jeopardize the life of the patient being
treated with antiretroviral drugs. Hyperlactatemia is asso-
ciated with the use of nucleoside reverse transcriptase inhi-
bitors (NRTI). The symptomsmay be benign or asymptomatic,
or life-threatening lactic acidosis syndrome (LAS). Lactic
acidosis is a rare but potentially life-threatening adverse
event and has to be considered in the differential diagnosis
of patients on HAART presenting with nausea, vomiting,
abdominal distension, bloating abdominal pains, and loss
of weight.1—3
In resource-limited settings it is difficult, if not impossi-
ble, to make a definitive diagnosis of lactic acidosis by
laboratory measurement of lactate. Point-of-care (POC)
devices are helpful and inexpensive for the measurement
of lactate levels. However, though they have been validated
in the intensive care unit (ICU) setting, they have not been
validated in the busy outpatient clinic. POC lactate measure-
ments assist with clinical decision-making in patients sus-
pected to have hyperlactatemia or lactic acidosis.4,5
Validation in the ICU setting has indicated reliability to
within  1 mmol/l of the laboratory measurement.6
The purpose of this study was to assess the sensitivity and
specificity of the handheld lactate analyzer (Accutrend1
lactate meter) in the diagnosis of hyperlactatemia/lactic
acidosis in patients on treatment with an NRTI-containing
regimen (stavudine) compared to lactate levels obtained
using the Beckman CX7 Synchron1 machine in a resource-
poor setting. Greys Hospital, Communicable Diseases Clinic
(CDC) is a tertiary level referral institution for patients in
western Kwazulu-Natal.
Materials and methods
This was a cross-sectional study of 120 patients on HAART,
treated with regimen 1 (lamivudine, stavudine, efavirenz, or
nevirapine) presenting with symptoms and/or recovering
from hyperlactatemia/lactic acidosis syndrome.
Lactate levels were obtained simultaneously on a single
venipuncture sample using the Accutrend1 lactate meter, a
handheld, battery-powered reflectance photometer manu-
factured by Roche Diagnostics, Mannheim, Germany (POC
device) and using the CX7 Synchron machine (chromophore
detection at 520 nm) manufactured by Beckman Coulter,
Fullerton, USA (laboratory lactate measurement; gold stan-
dard). The cost of a single test using the Accutrend1 meter
was US$1.40 and by laboratory method was $13.67.
Venipuncture was undertaken without a tourniquet after
the patient had been at rest for at least 15 min. The specimen
was transported to the laboratory on ice within 40 min of
collection. A plasma lactate level of less than 2.2 mmol/l wasconsidered as normal.7 Intra-assay precision was demon-
strated by the performance of consecutive analyses of
two control solutions (high and low lactate control concen-
trations).
Data were analyzed using linear regression analysis, Pear-
son’s correlation coefficient, and agreement and precision
with the Bland—Altman method.
Results
The sensitivity of the Accutrend1 lactate meter in identify-
ing patients with lactate levels at or above 2.2 mmol/l was
95.9% (95% CI 87.7—98.9%) with a specificity of 63.8% (95% CI
48.5—76.9%) when compared with the gold standard (Beck-
man CX7 Synchron machine) (Table 1).
The receiver operating characteristics (ROC) curve of the
quantitative Accutrend1 measurements using the reference
instrument (positive or negative according to the cutoff point
of 2.2 mmol/l) as the true state, shows that the area under
the curve is significantly different to the null hypothesis value
of 0.5 ( p < 0.001; Figure 1).
The test result variable(s): meter has at least one tie
between the positive actual state group and the negative
actual state group. The smallest cutoff value is the minimum
observed test value minus 1, and the largest cutoff value is
the maximum observed test value plus 1. All the other cutoff
values are the averages of two consecutive ordered observed
test values.
There were similar mean values obtained from the Accu-
trend1 meter (2.89 mmol/l) and the reference instrument
(2.78 mmol/l), as well as standard deviations (1.14 mmol/l
for Accutrend1 meter vs. 1.42 mmol/l for Beckman instru-
ment).
The positive predictive value for the Accutrend1 meter
was 80.5% (95% CI 70.3—87.9%) and the negative predictive
value was 90.9% (95% CI 74.5—97.6%). There was a modest
agreement between the methods (bias 0.113, 95% CI
2.103—2.329 mmol/l) (Figure 2).
There appears to be some discrepancy between the two
readings especially with regard to specificity. The Accu-
trend1 meter tends to over diagnose hyperlactatemia.
There was a modest correlation (0.63) between the Accu-
trend1 meter and the Beckman CX7 Synchron1 machine.
Regression analysis for the laboratory test against the meter
produced a slope of 0.5051 ( p < 0.0001) and an intercept of
1.4905 ( p < 0.0001) (Figure 3).
Figure 1 Receiver operating characteristics (ROC) curve of
quantitative Accutrend1 measurements. Diagonal segments
are produced by ties. Area under the curve 0.862, standard error
0.041, p < 0.001, 95% confidence interval 0.782—0.943.
Figure 3 Linear regression for the Accutrend1 meter against
Beckman instrument; y = 0.5051x + 1.4905.
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was longer for the laboratory test (mean 152 min, standard
deviation 63.2 min, range 45—240 min) than for the Accu-
trend1 meter (all values were 1 min); p < 0.0001.
Discussion
Lactic acidosis is a rare but potentially life-threatening
complication of antiretroviral treatment and is commonly
considered in the differential diagnosis of patients on HAART
presenting with nausea, vomiting, abdominal distension,
bloating abdominal pains, and loss of weight. POC devices
provide simple, accurate measurements of lactate levelsFigure 2 Bland—Altman plot of difference between lactate
measured by Accutrend1 analyzer and lactate measured by the
laboratory, and the mean of both methods.quickly and at low cost in resource-limited settings, where
access to definitive diagnosis by laboratory may be impos-
sible.4
POC devices have been validated in ICU settings as well as
in critically injured patients by Slomovitz et al.,5 Brinkert
et al.,8 and Boldt et al.9, but have not been validated in a
busy clinic setting.6
The sensitivity of the Accutrend1 lactate meter in the
diagnosis of hyperlactatemia was higher in our series than in
that reported by Brinkert et al.8 (95% vs. 84%), whilst the
specificity was lower (64% vs. 98%). The device is therefore a
useful tool for the screening of patients with hyperlactate-
mia/lactic acidosis,5,8,9 but is not a substitute for the labora-
tory measurement of lactate. The turnaround time was
significantly lower for the Accutrend1 than for the laboratory
result as reported by Boldt et al.9
The design of the Accutrend1 meter makes it user-
friendly and ideal for day-to-day use in communicable dis-
eases clinics. The costs of lactate testing were lower with the
Accutrend1 meter ($1.40 per test) than with the Beckman
($13.67 per test).
Conclusions
The Accutrend1 lactate analyzer is an appropriate device for
screening patients on HAART with symptoms of hyperlacta-
temia/lactic acidosis, but may need the laboratory method
to confirm the diagnosis of hyperlactatemia/lactic acidosis.
The Accutrend1 meter may supplement or support the clin-
ical diagnosis of hyperlactatemia/lactic acidosis. Failure to
confirm lactate levels with the laboratory method may result
in unnecessary withdrawal of antiretroviral therapy. The use
of this device decreases analytic and intervention time,
preventing further morbidity and mortality in patients on a
stavudine-based regimen.
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